Constructions Biscovery PRODUCTS COMPANY

Qualification of Ready-to-Use Cell-Based Assays for Potency to Support Immunology and Immunotherapy Drug Development

Jane Lamerdin, Ph.D.

Director R&D, Eurofins DiscoverX

March 27, 2020

BEBPA Virtual Conference


OUR EXPERTISE IN YOUR HANDS. DISCOVER CONFIDENTLY.





Immunotherapy Agents: Targeting Innate vs Adaptive Immunity





Therapeutic Modalities

TLR Agonists STING Agonists SIRPα / CD47

Checkpoint Inhibitors (anti-PD-1/PD-L1)

Checkpoint agonists (OX40, CD137, ICOS)

BiTEs, TRIKEs, etc




The Eurofins Discovery PRODUCTS COMPANY

Case Study 1 Development and Qualification of an Assay-Ready SIRP α (CD47) Signaling Assay

The SIRPα / CD47 Axis A Macrophage Immune Checkpoint

Ē






- SIRPα is a receptor expressed on macrophages and dendritic cells that promotes phagocytosis of foreign objects
- CD47, the ligand for SIRPα, is expressed on nearly all cells, but is significantly up-regulated in many tumor types, especially hematological malignancies such as AML and MDS
 - 'Don't eat me' signal that represses signaling via SIRPα and prevents phagoctyosis
- Blocking the CD47 / SIRPα axis (e.g. with anti-CD47 antibodies, engineered receptor decoys, anti-SIRPα antibodies and bispecific agents) promotes phagocytosis of the tumor
 - Anti-CD47 blockade has also been shown to enhance adaptive immunity (e.g. prime an anti-tumor cytotoxic T cell response)

Molecular MOA of SIRP α / CD47 Signaling Axis

🛟 eurofins

The Eurofins Discovery PRODUCTS COMPANY




Ę

PathHunter[®] SIRPα Signaling Assay: Assay Concept

🛟 eurofins

Co-culture SHP recruitment model based on β -galactosidase enzyme fragment complementation



Jurkat Ligand Presenting Cell Jurkat Ligand **CD47** Presenting Cell CD47 Anti-CD47 or SIRPα-FC BBBBBBBBBBBBB SIRPα SIRPα Substrate Jurkat Signaling Cells Substrate lurkat Signaling Cells No Light


Assay quantifies ligand-induced recruitment of SHP-1 to ITIM motifs in C-terminal tail of SIRP α in response to phosphorylation


Co-Culture SHP Recruitment Model

PathHunter[®] SIRPα (CD47) Signaling Assay

Construction Const

Co-culture model with stable surface expression of SIRPα and a stable functional response over 45+ passages







Development of RTU Assay Format for SIRPα Signaling Assay, with an Easy-to-Transfer Method

Content of the second s

The Eurofins Discovery PRODUCTS COMPANY






Comparable Performance to Continuous Culture Format

Format	HillSlope	IC ₅₀ (ng/mL)	S/B
Continuous Culture	-2.337	59.1	28
Cryopreserved (RTU)	-2.264	36.8	20

Multiple SIRPα Bioassay Lots Demonstrate Low Inter-Lot and Inter-Run Variability for Co-Culture Assay



SIRPα Lot A / CD47 Lot A

eurofins

DiscoverX

The Eurofins Discovery PRODUCTS COMPANY


- SIRPα Lot B / CD47 Lot B
- SIRPα Lot A / CD47 Lot B
- SIRPα Lot B / CD47 Lot A

- For each analyst, observed excellent inter-lot and inter-run reproducibility in IC₅₀
- More variability in IC₅₀ between analysts
- Variation between analysts not expected to impact relative potency measurements

SIRPa Bioassay Qualification: Study Design



Example plate layout



- Two analysts, multiple days
- 5 sample concentrations over range of 50-150% (50%, 75%, 100%, 125% and 150%)
- Each concentration evaluated 3 times by each analyst over a minimum of 3 days
 - Each sample tested in duplicate wells per dose with interleaved plate layout
- Specificity and forced degradation samples included

SIRPα Bioassay Qualification: Excellent Accuracy and Dilutional Linearity Over Range of 50-150%

Average


RP (%)

% RSD

% Accuracy

Relative

Bias, %



Accuracy	100.02%
Intermediate precision	6.5%
Relative Bias	1.6%
Dilutional Linearity	R ² = 1.000
Range	50-150%

Expected RP

(%)

	1	1	164				
	2	1	144				
150	3	1	145	140 E	F 00	00.7	0.0
150	4	2	140	149.5	5.96	99.7	-0.3
	5	2	148				
	6	2	156				
	1	1	123				
	2	1	125				
125	3 4	1	124	124.2	3.16	99.4	0.6
120	4	2	119	124.2	5.10	99.4	-0.6
	5	2	123				
	6	2	131				
	1	1	102				
	2	1	95				
	3	1	103	99.8	3.66	99.8	0.2
100	4	2	104	99.0	5.00	99.0	0.2
	5	2	98				
	6	2	97				
	1	1	75				
	2	1	73				
75	3	1	79	75.3	5.15	100.4	0.4
75	4	2	73	75.5	5.15	100.4	0.4
	5	2	81				
	6	2	71				
	1	1	55				
	2	1	52				
50	3	1	53	50.8	6.51	101.6	1.6
50	4	2	51	50.0	0.01	101.0	1.0
	5	2	48				
	6	2	46				

Measured RP

(%)

Analyst #

Exp #





The Eurofins Discovery PRODUCTS COMPANY

Case Study 2


Feasibility and Qualification of PathHunter[®] PD-1 Signaling Assay at Two Labs: Eurofins DiscoverX and Sartorius Stedim

PD-1 Signaling Assay Concept



The Eurofins Discovery PRODUCTS COMPANY

Quantify early step in PD-1 mediated inhibition of T cell activation: SHP recruitment



Mechanism of Action

Assay Design





Figure from Science Webinar Series, Part 5: Gordon J. Freeman, Ph.D.


Construction Const



Feasibility Study with Keytruda[®] and Opdivo[®] in the PathHunter[®] PD-1 Signaling Assay

Constructions Discovery PRODUCTS COMPANY

Initial qualification performed with 5 drug concentrations (50%, 75%, 100%, 125%, 150%) by a single analyst over multiple days with both Pembrolizumab and Nivolumab, with a minimum of 3 tests per concentration



Example Relative Potency Data for Pembrolizumab

Note: RP values calculated in PLA 3.0

Drug	Accuracy	Precision	Linearity
Keytruda (Pembrolizumab)	99.7%	4.8%	0.994
Opdivo (Nivolumab)	100.5%	6.0%	0.998

Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of **Merck & Co., Inc** Opdivo is a registered trademark of Bristol Myers Squibb

PD-1 Bioassay Qualification Study Design for Nivolumab (Sartorius Stedim)



The Eurofins Discovery PRODUCTS COMPANY

Study Design per ICH Guidelines Covering Range of 50-200%

Assessment #	Operator	Kit Lot#	Samples (%)	
1	А	1	50	100
2	В	1	50	200
3	В	1	100	Specificity
4	С	1	200	50
5	А	1	100	200
6	В	2	143	70
7	D	2	Heat-Treated 100%	Freeze/Thaw 100%
8	С	2	200	Heat-Treated 143%
9	Е	2	80	125



PD-1 Bioassay Qualification Results (Sartorious Stedim)

Nominal Concentration	Calculated Concentration	% Accuracy	Inaccuracy
50	46.1	92.2%	-7.8
50	45.7	91.4%	-8.6
50	47.5	95.0	-5.0
70	69.9	99.9	-0.1
80	68.4	85.5	-14.6
100	88.0	88.0	-12.0
100	97.3	97.3	-2.7
100	101.1	101.1	1.1
125	114.3	91.4	-8.6
143	144.3	100.9	0.9
200	197.1	98.6	-1.5
200	190.6	95.3	-4.7
200	190.4	95.2	-4.8
Specificity	0.7	N/A	N/A

Dilutional Linearity 250.0 Concentration $R^2 = 0.9906$ 200.0 150.0 Calculated 100.0 50.0 0.0 0.00 50.00 100.00 150.00 200.00 Nominal Concentration

Accuracy: within 14.6% across a range of 50- 200%
Intermediate precision: within 7% CV
Dilutional linearity: R² = 0.9906
Low variability and good reproducibility between different analysts and over multiple days

Summary



- Qualified MOA-reflective bioassays have been established for two important immunotherapy targets, PD-1 and SIRPα (CD47)
- Both assays were accurate and precise:
 - For PD-1: accuracy within 14.5% across a range of 50 to 200% and intermediate precision within 7% CV
 - For SIRPα: accuracy within 1.6% across a range of 50-150% and intermediate precision within 6.5% RSD
- Both assays demonstrated excellent dilutional linearity: R² value of 0.9906 for PD-1 and 1.000 for SIRPα
- Low variability and good reproducibility were observed between analysts and on different days
- Assays are suitable for QC lot release due to low variability, good accuracy and precision
- Ready-to-use format and optimized protocol transferred easily between sites for rapid implementation
- Assay-ready formats of Eurofins DiscoverX assays are available as off-the-shelf products or can be customized for your candidate molecule



Acknowledgements:

Sartorious Stedim BioOutsource Ltd

Laura McAleer

Lisa Blackwood

Eurofins DiscoverX

Mimi Nguyen Hyna Dotimas Ai Shih Jennifer Lin-Jones Alpana Prasad LiCi Zhu Neil Charter

For more information about our Products: <u>discoverx.com/bioassay</u>

For questions or to speak to an expert, contact: <u>JaneLamerdin@EurofinsUS.com</u> or <u>DRX_SupportUS@EurofinsUS.com</u>